Among them, pro-inflammatory organokines such as chemerin, progranulin, RBP4, FABP4, PAI-1, MCP-1, SPARC, SPARCL1, SAA, Fetuin A, and DPP4 have been shown to contribute to AT inflammation in pre-clinical animal models of obesity, suggesting that they could serve as potential therapeutic targets for obesity-induced inflammation. This evidence concerns the gene SPARCL1 and obesity disorder.